The short answer
MASH trials measure histological change on liver biopsy: resolution of steatohepatitis and improvement in fibrosis. These are scored by pathologists, carry documented inter-observer variability, and are surrogates for outcomes no trial can follow to completion.
Key facts
- Endpoint source
- Liver biopsy
- Scored by
- Pathologist judgement
- Known issue
- Inter-observer variability
- Mitigation
- Central reading, blinded
- Endpoint status
- Surrogate, not clinical outcome
- Sampling issue
- Biopsy samples a fraction of the organ
What is actually being measured
Two composite histological endpoints the field has converged on: resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis without worsening of steatohepatitis. Both combine several scored features into a binary outcome, which is a considerable amount of judgement compressed into a yes or no.
The variability problem
Two competent pathologists reading the same slide do not always agree, and the same pathologist reading it twice does not always agree with themselves. That variability is well documented and it adds noise to the endpoint, which reduces a trial's power to detect a real treatment effect and can obscure modest benefits.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why sampling makes it worse
A needle biopsy retrieves a small fraction of a large organ, and MASH is not uniformly distributed through the liver. Two samples from the same patient can score differently because the disease differs between sites, not because anything changed. This is a limitation of the measurement rather than of the analysis.
How trials manage it
Central reading by a small panel, blinded to treatment assignment and often to sequence, with paired biopsies read together. That controls the variability rather than eliminating it, and it is why the reading methodology in a MASH trial deserves attention: a well-run central read is a substantive part of the evidence.
Why they are surrogates at all
What matters clinically is cirrhosis, liver failure, transplant and death, which take decades. No trial can wait. Histology is used because it lies on the path to those outcomes and can be measured in a few years. It is a reasonable compromise, but still a compromise.
The consequence for approvals
Regulators grant accelerated approvals on surrogate endpoints with confirmatory outcome evidence required afterwards. So a MASH approval is a conditional statement about a probable benefit, not a settled one, and that distinction almost never survives into coverage of these decisions.
Frequently asked questions
Why do MASH trials need biopsies?
Because the endpoints are histological: inflammation, ballooning and fibrosis scored on tissue. No blood test substitutes for them at present.
How reliable is histological scoring?
It carries documented inter-observer variability, and biopsy sampling captures only a fraction of a non-uniformly affected organ.
Why are these endpoints accepted?
Because the real outcomes (cirrhosis, liver failure, death) take decades, and histology lies on the path to them and can be measured in years.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSanyal AJ et al., Phase 3 Trial of Semaglutide in MASH. NEJM 2025 (PMID 40305708)pubmed.ncbi.nlm.nih.gov
- PubMedNewsome PN et al., ESSENCE baseline characteristics and design. Aliment Pharmacol Ther 2024 (PMID 39412509)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · ESSENCE (NCT04822181)clinicaltrials.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- STEP UP: Testing Whether More Dose Means More EffectA phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults. Why raising the dose is not a trivial question and what a ceiling would mean.
- How a Molecule Lasts a Month Instead of a WeekWeekly dosing comes from albumin binding. Monthly dosing needs something else - an antibody, and the recycling receptor that keeps it in circulation.
- Blocking and Activating the Same Receptor, in One ModelTirzepatide activates GIPR; MariTide blocks it. Both work. A February 2026 mouse study finally compared the two directions under matched conditions.
- Why Population-Specific Trials Are RunOASIS 2 studied oral semaglutide in an East Asian population. Why obesity thresholds and drug response differ, and what a dedicated trial establishes.
- The Question Underneath the Lean Mass DebateAll weight loss costs fat-free mass, including diet and surgery. The real questions are whether incretins cost more, and whether it has functional consequences.